Manufacturer eyes potent compounds

Swiss pharmaceutical group Helsinn has announced plans to create a competitive manufacturing organization focused on highly potent compounds that includes both R&D and production capabilities. Financial investments and a new organization of manufacturing sites in Ireland and Switzerland are part of the strategy. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.